Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208543 | 0.88 | EPHX2 (0.77) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3944093 | 0.87 | EPHX2 (0.77) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3937303 | 0.86 | EPHX2 (0.77) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4921355 | 0.86 | HPGD (0.81) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3939273 | 0.85 | EPHX2 (1.00) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL14029874 | 0.84 | EPHX2 (0.72) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL8172365 | 0.83 | EPHX2 (0.71) | EPHX2HPGDNPC1KDM4E | |
| SCHEMBL3944127 | 0.83 | EPHX2 (1.00) | EPHX2HTTNPC1MAPTNAMPT | |
| SCHEMBL28284715 | 0.82 | EPHX2 (0.69) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT | |
| SCHEMBL3936504 | 0.82 | EPHX2 (1.00) | EPHX2HPGDSMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101495119-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-07-29 | — | — | CN | claimed |
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | claimed |
| CN-101495119-A | Soluble epoxide hydrolase inhibitors | ARETE THERAPEUTICS INC (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2046329-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Arete Therapeutics, INC. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2008016884-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032978-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885HPGD 97/4885SMN1; SMN2 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.